EGFR and brain neoplasm: Flow cytometry was used to demonstrate a stronger reaction with EMab-17 LN229/EGFR than with endogenous EGFR-expressing LN229 brain tumor cells (Fig. 1A), which indicated that EMab-17 is EGFR-specific.